Cue Biopharma Inc

-0.20 (-1.62%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)383.75M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$2.29 Million
Adjusted EPS-$0.37
See more estimates
10-Day MA$12.57
50-Day MA$12.50
200-Day MA$12.75
See more pivots

Cue Biopharma Inc Stock, NASDAQ:CUE

21 Erie Street, Cambridge, Massachusetts 02139
United States of America
Phone: +1.617.949.2680
Number of Employees: 50


Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded by Ronald D. Seidel III, Steven Almo, and, Rodolfo Chaparro on December 31, 2014 and is headquartered in Cambridge, MA.